DAY ONE BIOPHARMACEUTI

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

30 Oct 2024 15:01:00 By Nasdaq GlobeNewswire

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

16 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

30 Jul 2024 06:30:00 By Nasdaq GlobeNewswire

Day One Announces Oversubscribed $175.0 Million Private Placement

30 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

18 Jun 2024 07:30:00 By Nasdaq GlobeNewswire

Day One Announces Sale of Priority Review Voucher for $108 Million

30 May 2024 07:30:00 By Nasdaq GlobeNewswire

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

06 May 2024 15:30:00 By Nasdaq GlobeNewswire

Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

23 Apr 2024 14:56:39 By Nasdaq GlobeNewswire

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

26 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Day One Announces Two New Appointments to Board of Directors

17 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

19 Dec 2023 07:00:00 By Nasdaq GlobeNewswire

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

17 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference

14 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

06 Nov 2023 15:30:05 By Nasdaq GlobeNewswire

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

30 Oct 2023 07:00:00 By Nasdaq GlobeNewswire

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

11 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience

16 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

07 Aug 2023 15:30:00 By Nasdaq GlobeNewswire

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

12 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

Day One Announces Pricing of Public Offering of Common Stock

06 Jun 2023 21:31:14 By Nasdaq GlobeNewswire